Development of a binding model to protein tyrosine kinases for substituted pyrido [2,3-d]pyrimidine inhibitors

Journal of Medicinal Chemistry

Volumn 41, Issue 11, 1998, Pages 1752-1763

  Trumpp Kallmeyer, Susanne ^a   Rubin, J Ronald ^a   Humblet, Christine ^a   Hamby, James M ^a   Showalter, H D Hollis ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE;

ARTICLE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; MOLECULAR MODEL; PROTEIN DOMAIN; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; BACULOVIRIDAE; CHICKENS; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; HYDROGEN BONDING; INSECTS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032554818     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970634p     Document Type: Article

References (33)

1. SaltielA. R. Signal transduction pathways as drug targets. Sci. Am. Sci. Med. 1996, 2, 58-67.
2. MajeskyM.; Reidy, M.; Bowen-Pope, D.; Hart, C.; Wilcox, J.; Schwartz, S. PDGF ligand and receptor gene expression during repair of arterial injury. J. Cell Biol. 1990, 111, 2149-2158.
3. JacksonC. L.; Schwartz, S. M. Pharmacology of smooth muscle cell replication. Hypertension (Dallas) 1992, 20, 713-736.
4. BornfeldK. E. Intracellular signaling in arterial smooth muscle migration versus proliferation. Trends Cardiovasc. Med. 1996, 6, 143-151.
5. KelloffG. J.; Fay, J. R.; Steele, V. E.; Lubet, R. A.; Boone, C. W.; Crowell, J. A.; Sigman, C. C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemo-preventives. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 657-666.
6. HambyJ. M.; Connolly, C. J.; Schroeder, M. C.; Winters, R. T.; Showalter, H. D. H.; Panek, R. L.; Major, T. C.; Olsewsky, B.; Ryan, M. J.; Dahring, T.; Lu, G. H.; Keiser, J.; Amar, A. A.; Shen, C.; Kraker, A. J.; Slintak, V.; Nelson, J. M.; Fry, D. W.; Bradford, L.; Hallak, H.; Doherty, A. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 1997, 40, 2296-2303.
7. KlutchkoS. R.; Hamby, J. M.; Boschelli, D. H.; Wu, Z.; Kraker, A. J.; Amar, A. M.; Hartl, B. G.; Shen, C.; Klohs, W. D.; Steinkampf, R. W.; Driscoll, D. W.; Nelson, J. M.; Roberts, B. J.; Stoner, C. L.; Vincent, P. W.; Dykes, D. J.; Panek, R. L.; Lu, G. H.; Major, T. C.; Dahring, T. K.; Hallak, H.; Bradford, L. A.; Showalter, H. D. H.; Doherty, A. M. 2-Substituted aminopyrido[2,3-d]pyriinidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. Manuscript in preparation.
8. ConnollyC. J. C.; Hamby, J. M.; Schroeder, M. C.; Barvian, M.; Lu, G. H.; Panek, R. L.; Amar, A.; Shen, C.; Kraker, A. J.; Fry, D. W.; Klohs, W. D.; Doherty, A. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 7, 2415-2420.
9. (a) SchroederM. C.; Hamby, J. M.; Grohar, P. J.; Winter, R. T.; Connolly, C. J. C.; Showalter, H. D. H.; Kraker, A. J.; Amar, A. M.; Shen, C.; Lu, G. H.; Dahring, T. K.; Panek, R. L.; Major, T. C.; Doherty, A. M. The synthesis and SAR of pyrido[2,3-d]-pyrirnidine-2,7-diamines in the development of potent water soluble tyrosine kinase inhibitors. Presented at the National Medicinal Chemistry Symposium, Ann Arbor, MI, June 1996; Abstract No, 4.
10. (b) BlankleyC. J.; Doherty, A. M.; Hamby, J. M.; Panek, R. L.; Schroeder, M. C.; Showalter, H. D. H.; Connolly, C. J. Preparation of 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase-mediated cellular proliferation. PCT Int. Appl. WO 9615128 A2, 1996.
11. ZhengJ.; Trafny, E. A.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; Ten Eyck, L. F.; Sowadsky, J. M. 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr. 1993, D49, 362-365.
12. Schulze-GahmenU.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S.-H. Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentyladenine. Proteins: Struct. Funct. Genet. 1995, 22, 378-391.
13. HanksS. K.; Quinn, A. M. Protein kinase catalytic domain sequence database : Identification of conserved features of primary structure and classification of family members. Methods Enzymol. 1991, 200, 38-62.
14. De BondtH. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S. H. Crystal structure of cyclin-dependent kinase 2. Nature 1995, 363, 595-602.
15. OwenD. J.; Noble, M. E. M.; Garman, E. F.; Papageorgiou, A. C.; Johnson, L. N. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure 1995, 3, 467-482.
16. ZangF.; Strand, A.; Robbins, D.; Cobb, M. H.; Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 1994, 367, 704-711.
17. XuW.; Harrison, S. C.; Eck, M. J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997, 385, 595-602.
18. SicheriF.; Moarefi, I.; Kuriyan, J. Cystal structure of the Src family tyrosine kinase Hck. Nature 1997, 385, 602-609.
19. MohamadiM.; Schlessinger, J.; Hubbard, S. Structure of the FGF receptor tyrosine kinase domain reveals a novel auto-inhibitory mechanism. Cell 1996, 86, 577-587.
20. WilsonK. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V.; Bemis, G. W.; Fitsgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
21. PalmerB. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
22. MohamadiM.; McMahon, G.; Sun, L. T.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
23. BolenJ. B.; Penhallow, R. C.; Burkhard, A. L. Signal transduction by the src family of tyrosine protein kinase. In Encyclopedia of Cancer; Bertino, J., Ed.; Academic Press: San Diego, CA, 1997; pp 1657-1668.
24. Look; Molecular Applications Group445 Shennan AveSuite TPalo AltoCA 94306.
25. YamaguchiH.; Hendrickson, W. A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996, 384, 484-489.
26. HubbardS. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analogue. EMBO 1997, 16, 5572-5581.
27. LevittM. Accurate modeling of protein conformation by automatic segment matching. J. Mol. Biol. 1992, 226, 507-533.
28. Sybylmolecular modeling software; Tripos E & S6548 Clayton RdSt. Louis, MO 62117.
29. InsightII/Discover; Biosym/MSI9685 Scranton RdSan DiegoCA 92121-2777.
30. AllingerN. L.; Yuh, Y. H.; Lii, J. H. Molecular mechanics. The MM3 force field for hydrocarbonns. 1. J. Am. Chem. Soc. 1989, 111, 8551-9566.
31. DewarM. J. S.; Thiel, W. Ground states of molecules. The MNDO method, approximations and parameters. J. Am. Chem. Soc. 1977, 99, 4899.
32. PanekR. L.; Lu, G. H.; Klutchko, S. R.; Batley, B. L.; Dahring, T. K.; Hamby, J. M.; Hallak, H.; Doherty, A. M.; Keiser, J. A. In vitro pharmacological characterization of PD166285, a new broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 283, 1433-1444.
33. DahringT. K.; Lu, G. H.; Hamby, J. M.; Batley, B. L.; Kraker, J.; Panek, R. L. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 281, 1446-1456.